Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price in focus on growth in FY23 result

The Volpara Health Technologies Ltd (ASX:VHT) share price is under the spotlight after reporting a record FY23 result.

The Volpara Health Technologies Ltd (ASX: VHT) share price is under the spotlight after reporting a record FY23 result.

Volpara offers software relating to screening for cancer. It helps better analyse breast screening images to understand and advise on risk, while also providing software for healthcare professionals to do things more efficiently.

FY23 half-year result

Here are some of the highlights from the report for the 12 months to 31 March 2023:

  • Revenue rose 34% (or 20% in constant exchange rate terms) to NZ$35 million, compared to initial guidance of NZ$33.5 million to NZ$34.5 million
  • Underlying EBITDA (EBITDA explained) improved 57% to a loss of NZ$6.1 million
  • Net loss after tax improved by 40% to NZ$9.8 million

All three of its core products – analyics, patient hub/MRS and risk pathways saw strong revenue growth of 30%, 33% and 49%. The other (small) revenue categories of lung and genetic lab interfaces (along with other items) saw increases compared to last year.

Volpara has estimated that it has a software product that is used in more than 40% of the breast screening volume in the US. But, a significant portion of customers only use one Volpara product, giving “an excellent opportunity for the company to cross-sell additional products to its existing customer base.” Being successful with this could be a big boost for the Volpara share price.

The ASX healthcare share said that overall operating costs have “stabilised”. Stable costs with soaring revenue is a helpful combination.

FY24 guidance

Volpara said that it has set its guidance for FY24 revenue in constant currency terms of between NZ$40 million to NZ$42 million, which would be an increase of between 15% to 20% compared to FY23.

It has also guided that it expects to make underlying EBITDA of between NZ$0.5 million and a loss of NZ$2 million.

Volpara had a cash balance of NZ$12.7 million at 31 March 2023. It’s hoping to reach profitability, but it has established a NZ$10 million revolving credit facility with Kiwibank which could provide funding without diluting ownership.

Final thoughts on the Volpara share price

The ASX healthcare share is getting closer and closer to breakeven, while demonstrating strong revenue growth.

If it can sell more software to existing customers, then this would be a helpful boost for the average revenue per user (ARPU).

I think Volpara is a very promising business, and the lung cancer screening could provide an unexpected boost later this decade.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content